What is Wharton's jelly?
The umbilical cord is the tissue that connects the developing fetus to the placenta. Anatomically it contains three vessels — one umbilical vein that carries oxygenated blood from the placenta to the fetus, and two umbilical arteries that return deoxygenated blood from the fetus back to the placenta. The connective tissue that cushions and surrounds these vessels is called Wharton's jelly, named after the 17th-century English physician Thomas Wharton who first described it in 1656.
Histologically, Wharton's jelly is a gelatinous mucous connective tissue rich in glycosaminoglycans (especially hyaluronic acid), collagen fibers, and a population of stromal cells with strong mesenchymal characteristics. It is biologically young — at the time of birth, the cord has been functioning for nine months — and it is anatomically distinct from cord blood. Cord blood contains hematopoietic stem cells (used for transplants in hematologic disease). Wharton's jelly contains mesenchymal stem cells (used for tissue repair, immunomodulation, and inflammation control). These are two different populations with two different clinical uses, and the distinction matters when comparing protocols.
When a delivery team and the family consent to donation, Wharton's jelly can be isolated from the cord segment between the umbilical artery and the umbilical vein. The remaining tissue would otherwise be discarded after birth. This anatomical accessibility — without any invasive procedure to the mother or the newborn — is one of the reasons UC-MSCs became a preferred allogeneic source in modern stem-cell laboratories.
Why UC-MSCs are preferred over older sources
Mesenchymal stem cells can be isolated from bone marrow, adipose tissue, dental pulp, placenta, and umbilical cord. Each source produces cells that meet the formal definition of an MSC, but the cells differ meaningfully in yield, proliferation, immunological profile, and how invasive the donation procedure is. Across the last decade of published comparative data, UC-MSCs have moved to the front of the line for several reasons.
- High yield per donation. A single umbilical cord delivers millions of viable MSCs per gram of Wharton's jelly. A bone-marrow aspirate from an adult donor yields orders of magnitude fewer cells per volume, with significant inter-donor variability. UC-MSCs scale predictably.
- Naïve cells with high proliferative capacity. Cells isolated at birth have not accumulated decades of replicative wear, telomere shortening, or environmental insults. They divide more readily in culture, reach therapeutic doses faster, and demonstrate stronger paracrine activity in preclinical assays than adult-derived MSCs.
- Low immunogenicity. UC-MSCs express low levels of HLA class I and minimal HLA class II, which is the molecular basis for their immunoprivileged behavior. In practice this means allogeneic UC-MSC preparations can be administered without HLA matching in carefully screened protocols, and rejection events are rare in published cohorts.
- No painful or invasive donor procedure. Bone marrow aspirate requires general or regional anesthesia and a needle puncture of the iliac crest. Adipose-derived MSCs require liposuction. Wharton's jelly is obtained from tissue that would otherwise be discarded after delivery — the mother undergoes no additional procedure to donate.
- Strong immunomodulatory and paracrine profile. UC-MSCs secrete a robust panel of cytokines (IL-10, TGF-β, IDO), growth factors (HGF, VEGF, FGF-2), and extracellular vesicles. The combination supports their use as an immunomodulatory and tissue-supportive agent rather than a simple cell-replacement product.
- Standardized lot characterization. Because UC-MSCs come from a single donor and a single processing event, every lot can be characterized with flow cytometry, viability assays, and contamination panels before release. The variability that plagues bedside autologous preparations is moved upstream into a controlled laboratory environment.
Ethical sourcing — consent, traceability, and discarded tissue
Umbilical-cord stem cells are not embryonic stem cells. They are obtained from the post-natal umbilical cord, which is biological waste after a routine delivery. Mothers (and, where applicable, both parents) provide explicit, informed, written consent for tissue donation before the delivery. Consent is voluntary, can be withdrawn at any point before processing, and is separate from any medical decisions about the delivery itself. Donation does not change the clinical care the mother or newborn receive in any way.
Most ethical-grade UC-MSC programs source tissue specifically from planned C-section deliveries with consenting mothers. The reason is procedural: a scheduled C-section delivery occurs under controlled sterile field conditions, the cord can be handled without contamination, and the cold chain to the processing laboratory can be planned in advance. Vaginal-delivery cord tissue is biologically equivalent but harder to capture under research-grade sterile conditions in a hospital setting.
After collection, every donation is anonymized, assigned a unique lot identifier, and traceable end-to-end: hospital of origin, date of collection, donor screening results, processing facility, expansion passage number, viability at release, and clinic of administration. A reputable supplying laboratory can produce a Certificate of Analysis (CoA) for any given lot on request, and a reputable clinic will not infuse cells from a lot it cannot trace.
The ethical floor is straightforward: no donor is paid for the tissue beyond reasonable expense reimbursement permitted by local law; donor identity is protected; consent is documented; and the tissue would have been discarded had the family declined to donate. International standards from ISCT, AABB, and equivalent regional bodies converge on these same requirements.
Donor screening protocol — what every donor is tested for
Donor screening is the strongest safety filter in allogeneic stem-cell therapy. A compliant screening package, performed at the laboratory that processes the tissue (not at the receiving clinic), covers four pillars: a comprehensive donor health questionnaire, infectious disease serology, a laboratory panel, and a documented chain of custody.
- Donor health questionnaire. Personal and family medical history covering hereditary disease, genetic conditions, autoimmune disease, malignancy, transmissible illness exposure, lifestyle factors, recent travel to areas with endemic infections, recent vaccinations, and current medications. The questionnaire is administered before consent is signed and forms part of the permanent donor record.
- Infectious disease serology. Mandatory testing on every donor: HIV-1 and HIV-2 (antibody and NAT), Hepatitis B virus (HBsAg, anti-HBc, HBV NAT), Hepatitis C virus (anti-HCV and HCV NAT), Syphilis (treponemal test), CMV (anti-CMV IgM/IgG), and HTLV-I/II. Additional regional screens — Chagas disease, West Nile virus, Zika, malaria — are added based on donor geography and travel history.
- Laboratory panel and tissue testing. Complete blood count, basic metabolic panel, blood typing, and direct microbiological testing of the tissue itself (aerobic and anaerobic bacterial culture, fungal culture, mycoplasma) at multiple points in processing. Cells are not released for clinical use until contamination testing returns clean at the final passage.
- Chain of custody. Time-stamped documentation from collection through cryopreservation through release. Every transfer is signed, temperature-monitored, and recorded in a tamper-evident system. The receiving clinic should be able to follow the chain backward from infusion to donor on request.
A clinic that cannot produce — or refuses to produce — the screening documentation for a given lot is asking the patient to trust an unverifiable claim. Ask for a Certificate of Analysis. A compliant supplying laboratory issues one for every lot it releases.
Processing and expansion — sterile lab, GMP-aligned
Once tissue arrives at the processing facility — typically within hours of delivery, on a validated cold chain — Wharton's jelly is dissected from the cord segment, enzymatically or explant-cultured to release the mesenchymal cell population, and seeded into culture flasks in a defined medium. Early passages are characterized for morphology, adherence, and surface marker profile before being expanded further.
Modern processing aligns with Good Manufacturing Practice (GMP) principles: dedicated clean rooms with controlled HEPA-filtered air, gowned operators following written SOPs, environmental monitoring, and lot-by-lot release testing. In Mexico, the laboratories that supply cells to clinics operate under COFEPRIS authorizations specific to tissue and cellular processing, with additional sector standards under the relevant NOMs and adherence to international guidance where applicable.
Release testing covers three things. First, viability — ISCT guidance calls for ≥70%, and high-quality laboratories typically release at ≥95% viability at the final passage. Second, identity — flow cytometry confirming the MSC immunophenotype: positive for CD73, CD90, and CD105 (≥95% of the population), negative for the hematopoietic markers CD34, CD45, CD11b, CD14, CD19, HLA-DR (≤2% of the population). Third, function — assays demonstrating that the cells retain trilineage differentiation potential (osteogenic, adipogenic, chondrogenic) under standard inducing conditions.
Cells are then cryopreserved in defined freezing medium, banked, and released as needed for clinical use. The receiving clinic should know — and the patient should be able to ask — at what passage number the cells were cryopreserved, what the post-thaw viability was, and which lot specifically is being administered.
Allogeneic safety — what published cohorts show
The biological basis for the safety of allogeneic UC-MSC infusions is well established. Low HLA class I expression and minimal HLA class II expression mean these cells do not present strong immunological targets in the recipient. In practice this has translated into reassuring safety data across a growing body of published cohorts spanning orthopedic, autoimmune, and inflammatory indications.
The most common adverse events reported in the literature are transient and minor: low-grade fever in the hours after infusion, mild headache, transient chills, and short-lived injection-site discomfort for joint-injected protocols. Serious adverse events — clinically significant immune reactions, infection traced to the cell product, ectopic tissue formation, or tumor formation — have remained rare across thousands of treated patients in registries that publish safety outcomes. The most catastrophic reported events in regenerative medicine have generally traced back to poorly characterized autologous adipose-derived preparations administered outside any sterile chain, not to well-screened allogeneic UC-MSCs from licensed laboratories.
Two important caveats. First, safety is a population-level statement; individual response varies and the clinical team must screen for contraindications before any infusion. Second, the safety floor is only as strong as the supply chain: an unscreened or contaminated lot can cause serious harm regardless of source. This is why the screening, processing, and characterization standards described above are non-negotiable — not optional.
The molecular basis of immune privilege — beyond "HLA-low"
Saying UC-MSCs are "immunoprivileged" is a useful shorthand, but the underlying biology is more specific. Two layers explain why allogeneic Wharton's-jelly cells are generally tolerated. The first is what the cells do not display: they express low levels of HLA class I, little to no HLA class II (HLA-DR) on their surface in the resting state, and they lack the co-stimulatory molecules (CD80, CD86, CD40) that a T cell needs to mount a full rejection response. Without that second "go" signal, recipient T cells that encounter the cells tend toward anergy rather than activation.
The second layer is what the cells actively secrete. UC-MSCs produce a soluble, non-classical HLA molecule called HLA-G (including the secreted HLA-G5 isoform) that directly dampens T-cell, natural-killer-cell, and dendritic-cell activity. They also upregulate indoleamine 2,3-dioxygenase (IDO), an enzyme that depletes local tryptophan and starves proliferating T cells; release prostaglandin E2 (PGE2), which shifts the immune environment toward tolerance; and secrete transforming growth factor-β (TGF-β) and interleukin-10 (IL-10), both of which expand regulatory T cells. The net effect is an actively immunosuppressive micro-environment around the cells rather than a passively invisible one. Detailed characterization of these immunologic properties in umbilical-cord-derived cells has been published in the peer-reviewed literature, and understanding them is the difference between treating immune privilege as marketing and treating it as a defined, measurable cell property.
Sources: Nagamura-Inoue T, He H. Umbilical cord-derived mesenchymal stem cells: their advantages and potential clinical utility (low HLA-DR, lack of CD80/CD86, HLA-G5 and PGE2 immunosuppression). World J Stem Cells. 2014. · Dominici M, et al. Minimal criteria for defining multipotent mesenchymal stromal cells — ISCT position statement (HLA-DR-negative surface phenotype). Cytotherapy. 2006.
Quality standards and how the yield advantage is quantified
The identity criteria a clinical-grade UC-MSC must meet are not improvised by each laboratory. They trace to the International Society for Cell & Gene Therapy (ISCT) minimal-criteria position statement, which defines an MSC by plastic adherence, a specific surface-marker fingerprint (positive for CD73, CD90, CD105; negative for CD34, CD45, CD11b/CD14, CD19/CD79α, HLA-DR), and demonstrated trilineage differentiation into bone, cartilage, and fat. The World Health Organization has separately published a written standard for the flow-cytometric characterization of MSCs (WHO/BS.2019.2376) to harmonize how these markers are measured between laboratories. On the tissue-banking side, the American Association of Blood Banks (AABB) maintains accreditation standards for cellular-therapy and cord-tissue facilities that cover donor eligibility, collection, processing, labeling, and traceability — the same pillars described in the screening section above. A laboratory that can point to ISCT-conformant release criteria and recognized tissue-banking accreditation is operating to published standards, not house rules.
The yield advantage of cord tissue over bone marrow can also be put in concrete terms. Mesenchymal cells are a vanishingly small fraction of an adult marrow aspirate — on the order of 0.001% to 0.01% of mononuclear cells — whereas Wharton's jelly is a comparatively dense source of stromal cells that can be expanded with shorter doubling times in early passage. Review data report that the colony-forming-unit fibroblast frequency is higher in umbilical-cord tissue than in bone marrow, which is the practical reason a single cord donation reaches clinical quantities more readily, and more reproducibly, than repeated adult marrow harvests. This is a yield-and-consistency argument, not a claim that one source is therapeutically superior for every diagnosis.
Sources: Dominici M, et al. Minimal criteria for defining multipotent mesenchymal stromal cells — ISCT position statement. Cytotherapy. 2006. · WHO Expert Committee on Biological Standardization. Study report on flow-cytometric characterization of mesenchymal stromal cells (WHO/BS.2019.2376). 2019. · Nagamura-Inoue T, He H. Umbilical cord-derived mesenchymal stem cells: their advantages and potential clinical utility. World J Stem Cells. 2014.
Cryopreservation, passage number, and how potency is protected
Banked UC-MSCs spend most of their working life frozen. Quality therefore depends on two things a patient should be able to ask about: how well the cells survive thawing, and how many times they were expanded (the passage number) before being frozen. Both are measurable, and both should appear on the lot's Certificate of Analysis.
On viability, the published evidence is reassuring. In a controlled study that froze Wharton's-jelly UC-MSCs and re-tested them after a full year of cryopreservation, post-thaw viability remained at 93.81% (compared with 96.34% before freezing), and the cells retained their morphology, surface-marker profile, proliferative capacity, and chromosomal stability after thawing. Cells are stored in vapor- or liquid-phase liquid nitrogen (roughly −150 °C to −196 °C) in a defined freezing medium that typically uses DMSO as the cryoprotectant; ISCT guidance treats ≥70% viability as the release floor, and high-quality laboratories generally release well above 90%.
On passage number, the principle is that earlier is better. Each population doubling brings cells closer to replicative senescence — a state in which they stop dividing and their therapeutic activity declines. Comparative culture data tracking UC-MSCs from passage 3 through passage 12 show cumulative population doublings climbing with passage and proliferative behavior changing as cells age in culture, which is exactly why clinical-grade banks cap expansion at low passages rather than pushing cells to their division limit. The patient-facing version of this is simple: ask at what passage the cells were frozen, and favor laboratories that release early-passage lots.
Sources: Zhang M, et al. Study of the biological characteristics of human umbilical cord mesenchymal stem cells after long-time cryopreservation. Cell Tissue Bank. 2022. · Wang X, et al. Efficient expansion and delayed senescence of hUC-MSCs by microcarrier–bioreactor system. Stem Cell Res Ther. 2023. · Dominici M, et al. Minimal criteria for defining multipotent mesenchymal stromal cells — ISCT position statement. Cytotherapy. 2006.
What published clinical cohorts have reported
The conservative way to read the UC-MSC literature is as a body of early-phase trials and follow-up cohorts that report safety and preliminary signals — not as proof of cure for any indication. With that framing, several published studies give patients concrete, peer-reviewed numbers to review with their physician.
In immune thrombocytopenia (ITP), a 2024 prospective single-arm phase I trial of human UC-MSCs in refractory patients reported an overall response rate of 44.4% (8 of 18 patients), with most adverse events graded mild to moderate. In systemic lupus erythematosus, a six-year follow-up study of umbilical-cord MSC transplantation reported on long-term safety in a treated cohort, and a separate randomized, double-blind, placebo-controlled trial evaluated allogeneic umbilical-cord MSCs in lupus nephritis. In severe COVID-19, a double-blind, randomized, placebo-controlled phase 1/2a trial of UC-MSCs reported safety and survival signals in acute respiratory distress syndrome. These cohorts are individually small and disease-specific; none should be generalized into a promise for a different condition.
Two structural advantages help explain why UC-MSCs are studied so heavily. First, yield and proliferation: review data report that colony-forming-unit fibroblast frequency is higher in umbilical-cord tissue than in bone marrow, with early-passage doubling times on the order of two to three days — so a single donation expands to clinical quantities more readily than an adult marrow aspirate. Second, tissue-homing: the same literature documents a tendency of UC-MSCs to accumulate in damaged or inflamed regions after administration, which is the proposed basis for their immunomodulatory, tissue-supportive role rather than direct cell replacement.
Sources: Chen Y, et al. Efficacy and safety of human umbilical cord-derived mesenchymal stem cells in refractory immune thrombocytopenia: a phase I trial. Signal Transduct Target Ther. 2024. · Wang D, et al. Long-term safety of umbilical cord mesenchymal stem cells transplantation for SLE: a 6-year follow-up study. Clin Exp Med. 2017. · Deng D, et al. A randomised, double-blind, placebo-controlled trial of allogeneic umbilical cord-derived MSC for lupus nephritis. Ann Rheum Dis. 2017. · Lanzoni G, et al. Umbilical cord mesenchymal stem cells for COVID-19 ARDS: a double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med. 2021. · Nagamura-Inoue T, He H. Umbilical cord-derived mesenchymal stem cells: their advantages and potential clinical utility. World J Stem Cells. 2014.
How UC-MSCs compare to adipose- and bone-marrow-derived MSCs
Each MSC source has legitimate clinical uses; none is universally superior for every indication. The table below summarizes the practical differences a patient should understand before a clinic recommends one source over another.
| Attribute | UC-MSC (Wharton's jelly) | Adipose (AD-MSC) | Bone marrow (BM-MSC) |
|---|---|---|---|
| Donor procedure | None for mother/newborn — tissue otherwise discarded | Liposuction under local or general anesthesia | Aspiration from iliac crest under anesthesia |
| Source type | Allogeneic (donor) | Typically autologous, sometimes allogeneic | Typically autologous, sometimes allogeneic |
| Cell age (biological) | Naïve — birth-derived, no replicative wear | Donor age — accumulated environmental insults | Donor age — declining proliferation with age |
| Yield per donation | High and predictable | Moderate to high, donor-dependent | Low to moderate, donor-dependent |
| Proliferative capacity | Very high in culture | Moderate | Lower, declines with age |
| Immunogenicity | Low (HLA-low, immunoprivileged) | Low when autologous; moderate allogeneic | Low when autologous; moderate allogeneic |
| Standardized dosing | Yes — lot-characterized banking | Variable, bedside preparations | Variable, bedside preparations |
| Common clinical uses | Systemic immunomodulation, multi-joint, IV anti-inflammatory | Local injection, orthopedic, aesthetic | Orthopedic, hematologic (BMAC distinct from BM-MSC) |
Neither table nor any clinic conversation replaces a personalized medical evaluation. A responsible physician will recommend the source most appropriate to the specific diagnosis, route of administration, and patient profile — not the source with the strongest marketing.
Frequently asked questions
Yes, when sourced under explicit, informed, written consent from the mother. The umbilical cord is biological waste after delivery — Wharton's jelly is obtained from tissue that would otherwise be discarded, without any additional procedure on the mother or the newborn. Cord stem cells are not embryonic stem cells; they are post-natal stromal cells from a routine delivery. Reputable programs document consent, anonymize the donor, and never pay beyond reasonable expense reimbursement.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
UC-MSCs express low HLA class I and minimal HLA class II, which makes them immunoprivileged. In published cohorts, allogeneic UC-MSC infusions have not required HLA matching and rejection events have remained rare across thousands of treated patients. Transient minor effects — low-grade fever, mild headache, transient chills — are the most commonly reported, and serious immune reactions are uncommon when cells come from a screened, licensed laboratory. As with any biologic, the clinical team must screen for contraindications before any infusion.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
The donor is a consenting mother whose delivery — typically a planned C-section under controlled sterile field — yields the umbilical cord from which Wharton's jelly is isolated. Screening is performed at the processing laboratory and covers a donor health questionnaire, infectious disease serology (HIV, HBV, HCV, syphilis, CMV, HTLV at minimum, plus regional screens), routine laboratory panel, direct microbiological testing of the tissue, and a documented chain of custody. A Certificate of Analysis is issued for every lot.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Properly banked UC-MSCs remain viable across long-term frozen storage. In a controlled study that re-tested Wharton's-jelly UC-MSCs after a full year of cryopreservation, post-thaw viability was 93.81% (versus 96.34% before freezing), and the cells kept their morphology, surface markers, proliferative capacity, and chromosomal stability. Cells are stored in liquid nitrogen (roughly −150 °C to −196 °C) in a defined medium that typically uses DMSO as the cryoprotectant. ISCT guidance treats ≥70% viability as the release floor; reputable laboratories generally release well above 90%. Ask for the post-thaw viability of your specific lot — it is recorded on the Certificate of Analysis (Zhang M, et al., Cell Tissue Bank, 2022).
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Yes — passage number matters. Each population doubling moves cells closer to replicative senescence, the point at which they stop dividing and lose therapeutic activity. Comparative culture data tracking UC-MSCs from passage 3 to passage 12 show cumulative population doublings rising and proliferative behavior changing as the cells age in culture, which is why clinical-grade banks cap expansion at low passages rather than pushing cells to their limit. There is no single universal number, but earlier-passage lots are generally preferred. Ask at what passage your cells were frozen (Wang X, et al., Stem Cell Res Ther, 2023; ISCT criteria — Dominici M, et al., Cytotherapy, 2006).
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Their tolerated behavior comes from two things. First, what they do not display: low HLA class I, little or no HLA class II (HLA-DR) at rest, and an absence of the co-stimulatory molecules (CD80, CD86, CD40) a T cell needs to mount full rejection — so recipient T cells tend toward anergy. Second, what they actively secrete: a soluble non-classical molecule called HLA-G (including the HLA-G5 isoform) that suppresses T, NK and dendritic cells; the enzyme IDO, which starves proliferating T cells of tryptophan; prostaglandin E2 (PGE2); and TGF-β and IL-10, which expand regulatory T cells. The result is an actively immunosuppressive micro-environment, not just an invisible cell. These properties are defined and measurable, not marketing (Nagamura-Inoue T, He H, World J Stem Cells, 2014).
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
They answer two different questions. ISCT (International Society for Cell & Gene Therapy) defines what an MSC is — plastic adherence, a CD73/CD90/CD105-positive and CD34/CD45/HLA-DR-negative surface fingerprint, and trilineage differentiation — and the WHO has published a written standard (WHO/BS.2019.2376) for measuring those markers by flow cytometry consistently between labs. AABB (American Association of Blood Banks) accredits the facility and the process: donor eligibility, collection, processing, labeling, and end-to-end traceability of cellular-therapy and cord-tissue products. In short, ISCT tells you the cell is the right cell; AABB-style accreditation tells you it was collected and handled to a recognized standard. A laboratory that can point to both is operating to published standards rather than house rules (ISCT — Dominici M, et al., Cytotherapy, 2006; WHO/BS.2019.2376).
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Long-term safety is followed through published clinical cohorts and follow-up studies in the peer-reviewed literature, which is publicly accessible on databases such as PubMed and PubMed Central. Examples include a six-year follow-up of umbilical-cord MSC transplantation in systemic lupus erythematosus, multi-year autoimmune cohorts, and meta-analyses pooling adverse-event data across trials. In addition, interventional trials are registered on public registries such as ClinicalTrials.gov and the WHO ICTRP before they begin. These sources let a patient or physician look up the actual reported safety record rather than rely on a clinic's summary — though the data should be read as condition-specific and early-phase, not as proof of cure (Wang D, et al., Clin Exp Med, 2017).
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Yes, though they should be read as early-phase safety and preliminary-signal data rather than proof of cure. A 2024 phase I trial of UC-MSCs in refractory immune thrombocytopenia reported a 44.4% overall response rate (8 of 18 patients). A six-year follow-up study reported long-term safety of umbilical-cord MSC transplantation in systemic lupus erythematosus, and a randomized, placebo-controlled trial evaluated allogeneic UC-MSCs in lupus nephritis. A double-blind, randomized, placebo-controlled phase 1/2a trial studied UC-MSCs in severe COVID-19 ARDS. These cohorts are small and disease-specific — discuss what they mean for your particular diagnosis with a physician (Chen Y, et al., 2024; Wang D, et al., 2017; Deng D, et al., 2017; Lanzoni G, et al., 2021).
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Yes — private cord-tissue banking services do exist and are offered at the time of delivery for the patient's own future use (autologous) or, in some programs, for sibling use. This is a separate decision from allogeneic UC-MSC therapy. If you are a new or expectant parent, talk to your obstetric team well before delivery — private banking requires advance consent, contracting, and a collection kit at the hospital. For adults seeking treatment now, autologous cord banking is not an option (your own cord tissue was not preserved at birth in most cases), which is one of the reasons allogeneic UC-MSC protocols exist.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Pricing depends on diagnosis, route of administration, total cell dose, and whether the protocol is single-session or multi-session. COFEPRIS-aligned UC-MSC protocols in Cancún are typically a fraction of US cash-pay rates for equivalent allogeneic preparations — but we do not publish fixed figures, because the binding number depends on your specific protocol. Every quote should be in writing, on letterhead, and itemized — Regeneris delivers a personalized written quote after a free medical evaluation; see our pricing page for how that works.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Yes. The laboratories that process Wharton's jelly into clinical UC-MSC preparations operate under COFEPRIS authorizations specific to tissue and cellular processing. The clinics that administer them operate under their own COFEPRIS Aviso de Funcionamiento and Aviso de Publicidad, and the treating physician must hold an active cédula profesional. The full regulatory framework is described on our safety and COFEPRIS page.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
UC-MSCs are biologically younger, available in higher and more predictable yields, and can be standardized lot-by-lot in a regulated laboratory. Autologous adipose and bone marrow preparations avoid the allogeneic question entirely but vary by donor age and yield, and bedside preparations are harder to characterize. Neither is universally better — the right choice depends on diagnosis, route of administration, and patient profile. A responsible clinic recommends the source appropriate to the case, not the source with the strongest marketing.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
No. Allogeneic culture-expanded MSC preparations — including UC-MSCs — sit inside the FDA's IND pathway in the United States, which means they can only be administered inside registered clinical trials in that jurisdiction. The FDA framework does not apply outside US jurisdiction. In Mexico, equivalent preparations are administered under COFEPRIS-regulated medical practice, provided the clinic, the supplying laboratory, and the physician all hold the correct authorizations.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Scientific evidence
References
- Wang D, et al.. Long-term safety of umbilical cord mesenchymal stem cells transplantation for systemic lupus erythematosus: a 6-year follow-up study. Clinical and Experimental Medicine. 2017. DOI: 10.1007/s10238-016-0427-0
- Deng D, et al.. A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis. Annals of the Rheumatic Diseases. 2017. DOI: 10.1136/annrheumdis-2017-211073
- Cai J, et al.. Umbilical cord mesenchymal stromal cell with autologous bone marrow cell transplantation in established type 1 diabetes: a pilot randomized controlled open-label clinical study to assess safety and impact on insulin secretion. Diabetes Care. 2016. DOI: 10.2337/dc15-0171
- Hu J, et al.. Long term effects of the implantation of Wharton's jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endocrine Journal. 2013. DOI: 10.1507/endocrj.EJ12-0343
- Lanzoni G, et al.. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1/2a, randomized controlled trial. Stem Cells Translational Medicine. 2021. DOI: 10.1002/sctm.20-0472
- Shi L, et al.. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduction and Targeted Therapy. 2021. DOI: 10.1038/s41392-021-00488-5
This bibliography is provided for educational purposes. It does not constitute medical advice and does not imply that any cited study endorses Regeneris Therapy or guarantees a clinical outcome.
Information for educational purposes only. Stem cell therapy is investigational for many indications; individual outcomes vary and depend on diagnosis, prior treatments, and overall health. Nothing on this page is a guarantee of result, and no protocol should be initiated without a personalized medical evaluation by a licensed physician.